

Enzymatic Therapy

NATURAL MEDICINES®

December 10, 2003

1173 01 JAN - 2 0004

Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 810
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740




RE: Label Claims/Disclaimers

Dear Sir or Madam:

This letter is to notify you that the following product is Manufactured, Packed, and/or Distributed by Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 has a label that contains a statement provided by section 403(r)(6) of the Federal Food, Drug and Cosmetic Act. Enzymatic Therapy, Inc. wishes to take advantage of the exemption to section 201(g)(1)(C) of the act and comply with section 403(r)(6) of the act. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

<u>PRODUCT NAME</u>	<u>STATEMENTS</u>	<u>INGREDIENT(S) TO WHICH THE CLAIM REFERS</u>
Super Milk Thistle®	The patented Phytosome™ technology, which combines one part standardized milk thistle extract with two parts phosphatidylcholine, dramatically improves absorption. Research indicates Phytosomes are absorbed more effectively than non-Phytosome™ products.*	Milk Thistle Fruit Phytosome, Artichoke Flower Leaf Extract, Dandelion Root Extract, Licorice Root and Rhizome Extract

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: 

Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 12/10/03

825 Challenger Drive
Green Bay, WI 54311-8328
Ph: 920-469-1313
Fax: 888-570-6460
www.enzy.com

975 0162


LET

13470

Super Milk Thistle 81e

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,

A handwritten signature in black ink that reads "Michael P. Devereux". The signature is written in a cursive style with a large, prominent initial "M".

Michael P. Devereux
Chief Financial Officer